BUON 24 , 8490 (2019)
Future research should focus on optimizing dosing strategies, clarifying the mechanisms underlying individual differences in treatment response, and exploring their potential in combination with novel therapies, aiming to provide better management strategies for motor fluctuations

A large panel of cytokines, chemokines and growth factors was measured using a pre-defined, commercially available, Luminex kit from Millipore (Burlington, MA) which included the cytokines interleukin (IL)-1, IL-1, IL-1RA, IL-2, IL-3, IL-4, IL-6, IL-7, IL-8, IL-10, IL-12p40, IL-12p70, IL-15, IL-17A, interferon (IFN)-2, IFN-, tumor necrosis factor (TNF)-, TNF-, granulocyte colony-stimulating factor (GCSF), granulocyte-macrophage colony-stimulating factor (GMCSF), epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), monocyte chemoattractant protein-1 (MCP1/CCL2), IFN-induced protein/chemokine (C-X-C motif) ligand 10 (IP10/CXCL-10), macrophage inflammatory protein-1 alpha (MIP1/CCL3), MIP-1 beta (MIP1/CCL4), and eotaxin (CCL11)
EBV Rta and Zta have been reported to alter mitochondrial membrane potential, which may imply an increase of ROS production [66]